2026-10-12T19:59:07Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33920953 2026-09-18T05:49:56Z category_90 portal_316 item_type_3 month_year_09_2026

Data Sheet 1_A novel minimally humanized mouse model of aniridia for preclinical evaluation of CRISPR gene editing strategies.pdf Seyedeh Zeinab Mirjalili Mohanna (25070548) Andrea J. Korecki (25070551) Pardis Kazemian (25070554) Tess C. Lengyell (25070557) Bethany A. Adair (25070560) Blair R. Leavitt (5927573) Elizabeth M. Simpson (24853672) Genetic Engineering base editing (BE) cortical neurons CRISPR genome editing lipid nanoparticle (LNP) ocular disorder paired box 6 gene ribonucleoprotein complex (RNP) Introduction<p>Aniridia is a rare congenital vision-loss disorder primarily caused by variants in the paired box 6 (PAX6) gene. Current treatments do not maintain vision long term, nor address the underlying disease mechanism. CRISPR-mediated genome editing holds great promise for treating genetic diseases but requires demonstration of efficacy on human DNA to support translational relevance. The aim of this work was to generate and test a minimally humanized mouse model of aniridia, carrying a FLAG-tagged Pax6 and the most common recurring pathogenic aniridia-patient variant, introduced for the first time in mice.</p>Methods<p>Ocular assessments (gross examination, slit lamp imaging, and fluorescent and confocal microscopy) were performed in mice homozygous for humanization and heterozygous for the variant, paralleling patients. Mice were examined immediately post-wean and at adulthood, with the former chosen as a likely time for treatment initiation. As an exploratory proof-of-principle, a lipid nanoparticle-delivered adenine base editor (ABE8e) was tested to demonstrate the utility of the model.</p>Results<p>Ocular assessments revealed the expected phenotypes for an aniridia mouse model, supporting successful generation and phenotypic validation of the humanized mouse. The ABE8e treatment resulted in a modest correction (4.8% ± 0.4% SEM) of the pathogenic variant in clinically relevant ex vivo cortical neurons.</p>Discussion<p>Although designed for the development of genome editing therapies, this humanized mouse is also applicable to other therapies requiring interaction with human DNA or RNA. It also enables evaluation of nonsense-suppression drugs since the readthrough proteins retain the FLAG tag. More broadly, this methodology is applicable to other pathogenic variants for aniridia, CRISPRa approaches, and other genetic diseases for which CRISPR-based therapy holds promise.</p> 2026-09-18T05:49:56Z Dataset Dataset 10.3389/fgeed.2026.1910209.s001 https://figshare.com/articles/dataset/Data_Sheet_1_A_novel_minimally_humanized_mouse_model_of_aniridia_for_preclinical_evaluation_of_CRISPR_gene_editing_strategies_pdf/33920953 CC BY 4.0